Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DCE MRI with Ferumoxytol for Pancreatic Cancer
NCT02070705Terminated
- Sponsor
- OHSU Knight Cancer Institute
- Start
- Jan 2014
- Primary completion
- Aug 2024
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Open-label trial of ferumoxytol in pancreatic adenocarcinoma (PDAC), intraductal papillary mucinous neoplasm of the pancreas (IPMN) and familial pancreatic cancer (FPC), sponsored by OHSU Knight Cancer Institute. Started Jan 2014; status: terminated.
02
Drugs
ferumoxytol
03
Conditions
pancreatic adenocarcinoma (PDAC)intraductal papillary mucinous neoplasm of the pancreas (IPMN)familial pancreatic cancer (FPC)
Beyond the preview
Go deeper on NCT02070705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02070705.